{"entity":{"type":"insider","cik":"0001677455","url":"/insider/0001677455","json_url":"/insider/0001677455.json","name":"Parschauer Karah Herdman","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":39,"n_filings":35,"first":"2018-05-10","last":"2026-08-04","span_basis":"filed_date"},"name_variants":[{"name":"Parschauer Karah Herdman","source":"filing","n_filings":35,"first_seen":"2018-05-10","last_seen":"2026-08-04"}],"transactions":[{"id":6136081,"accession":"0001193125-26-332547","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-332547","line_url":"/filing/0001193125-26-332547#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1900.0,"shares_display":"1,900","price_per_share":24.92,"price_display":"24.92","price_state":"stated","total_value":47348.0,"total_display":"47,348.00","total_whole":"47,348","shares_owned_after":92562.0,"shares_owned_after_display":"92,562","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-03","filed_date":"2026-08-04","scope":"insider"},{"id":5987727,"accession":"0001677455-26-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001677455-26-000002","line_url":"/filing/0001677455-26-000002#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1899.0,"shares_display":"1,899","price_per_share":24.62,"price_display":"24.62","price_state":"stated","total_value":46753.38,"total_display":"46,753.38","total_whole":"46,753","shares_owned_after":94462.0,"shares_owned_after_display":"94,462","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-15","filed_date":"2026-06-15","scope":"insider"},{"id":5809735,"accession":"0001193125-26-100309","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-100309","line_url":"/filing/0001193125-26-100309#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3508.0,"shares_display":"3,508","price_per_share":22.67,"price_display":"22.67","price_state":"stated","total_value":79526.36,"total_display":"79,526.36","total_whole":"79,526","shares_owned_after":66820.0,"shares_owned_after_display":"66,820","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-10","filed_date":"2026-03-10","scope":"insider"},{"id":5809732,"accession":"0001193125-26-100309","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-100309","line_url":"/filing/0001193125-26-100309#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6018.0,"shares_display":"6,018","price_per_share":21.4,"price_display":"21.40","price_state":"stated","total_value":128785.2,"total_display":"128,785.20","total_whole":"128,785","shares_owned_after":70328.0,"shares_owned_after_display":"70,328","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-06","filed_date":"2026-03-10","scope":"insider"},{"id":5797275,"accession":"0001193125-26-089111","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-089111","line_url":"/filing/0001193125-26-089111#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8135.0,"shares_display":"8,135","price_per_share":22.8,"price_display":"22.80","price_state":"stated","total_value":185478.0,"total_display":"185,478.00","total_whole":"185,478","shares_owned_after":76346.0,"shares_owned_after_display":"76,346","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-03","scope":"insider"},{"id":4962003,"accession":"0001677455-25-000005","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001677455-25-000005","line_url":"/filing/0001677455-25-000005#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2450.0,"shares_display":"2,450","price_per_share":31.17,"price_display":"31.17","price_state":"stated","total_value":76366.5,"total_display":"76,366.50","total_whole":"76,367","shares_owned_after":73271.0,"shares_owned_after_display":"73,271","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-12","filed_date":"2025-09-12","scope":"insider"},{"id":5093165,"accession":"0001570562-25-000046","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001570562-25-000046","line_url":"/filing/0001570562-25-000046#line-1","is_derivative":false,"issuer_cik":"0001570562","issuer_name":"Evolus, Inc.","issuer_ticker":"EOLS","issuer_name_source":null,"issuer_url":"/issuer/0001570562","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12888.0,"shares_display":"12,888","price_per_share":12.9939,"price_display":"12.99","price_state":"stated","total_value":167465.3832,"total_display":"167,465.38","total_whole":"167,465","shares_owned_after":32183.0,"shares_owned_after_display":"32,183","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-12","filed_date":"2025-03-14","scope":"insider"},{"id":4791009,"accession":"0000950170-25-032798","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-032798","line_url":"/filing/0000950170-25-032798#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12846.0,"shares_display":"12,846","price_per_share":42.1,"price_display":"42.10","price_state":"stated","total_value":540816.6,"total_display":"540,816.60","total_whole":"540,817","shares_owned_after":75287.0,"shares_owned_after_display":"75,287","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-03","filed_date":"2025-03-04","scope":"insider"},{"id":4263631,"accession":"0000950170-25-030639","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-030639","line_url":"/filing/0000950170-25-030639","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2990.0,"shares_display":"2,990","price_per_share":42.884247491638796,"price_display":"42.88","price_state":"stated","total_value":128223.9,"total_display":"128,223.90","total_whole":"128,224","shares_owned_after":55751.0,"shares_owned_after_display":"55,751","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-27","filed_date":"2025-03-03","scope":"insider","n_lines":2},{"id":2460834,"accession":"0000950170-24-072621","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-072621","line_url":"/filing/0000950170-24-072621#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9806.0,"shares_display":"9,806","price_per_share":45.0,"price_display":"45.00","price_state":"stated","total_value":441270.0,"total_display":"441,270.00","total_whole":"441,270","shares_owned_after":57981.0,"shares_owned_after_display":"57,981","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-12","filed_date":"2024-06-12","scope":"insider"},{"id":2080934,"accession":"0000950170-24-026666","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-026666","line_url":"/filing/0000950170-24-026666#line-3","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3756.0,"shares_display":"3,756","price_per_share":53.76,"price_display":"53.76","price_state":"stated","total_value":201922.56,"total_display":"201,922.56","total_whole":"201,923","shares_owned_after":67340.0,"shares_owned_after_display":"67,340","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-01","filed_date":"2024-03-05","scope":"insider"},{"id":2428251,"accession":"0001570562-24-000005","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001570562-24-000005","line_url":"/filing/0001570562-24-000005#line-1","is_derivative":false,"issuer_cik":"0001570562","issuer_name":"Evolus, Inc.","issuer_ticker":"EOLS","issuer_name_source":null,"issuer_url":"/issuer/0001570562","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11931.0,"shares_display":"11,931","price_per_share":13.1366,"price_display":"13.14","price_state":"stated","total_value":156732.7746,"total_display":"156,732.77","total_whole":"156,733","shares_owned_after":31243.0,"shares_owned_after_display":"31,243","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-30","filed_date":"2024-02-02","scope":"insider"},{"id":8607315,"accession":"0001209191-23-027601","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-027601","line_url":"/filing/0001209191-23-027601#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4378.0,"shares_display":"4,378","price_per_share":45.0,"price_display":"45.00","price_state":"stated","total_value":197010.0,"total_display":"197,010.00","total_whole":"197,010","shares_owned_after":51982.0,"shares_owned_after_display":"51,982","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-04","filed_date":"2023-05-05","scope":"insider"},{"id":8543936,"accession":"0001209191-23-016047","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-016047","line_url":"/filing/0001209191-23-016047#line-3","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3161.0,"shares_display":"3,161","price_per_share":45.25,"price_display":"45.25","price_state":"stated","total_value":143035.25,"total_display":"143,035.25","total_whole":"143,035","shares_owned_after":56139.0,"shares_owned_after_display":"56,139","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-03","scope":"insider"},{"id":6652316,"accession":"0001209191-22-016931","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-016931","line_url":"/filing/0001209191-22-016931#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5140.0,"shares_display":"5,140","price_per_share":62.95,"price_display":"62.95","price_state":"stated","total_value":323563.0,"total_display":"323,563.00","total_whole":"323,563","shares_owned_after":34438.0,"shares_owned_after_display":"34,438","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-07","filed_date":"2022-03-08","scope":"insider"},{"id":6243560,"accession":"0001209191-22-015811","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-015811","line_url":"/filing/0001209191-22-015811#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2886.0,"shares_display":"2,886","price_per_share":66.62,"price_display":"66.62","price_state":"stated","total_value":192265.32,"total_display":"192,265.32","total_whole":"192,265","shares_owned_after":25472.0,"shares_owned_after_display":"25,472","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-01","filed_date":"2022-03-03","scope":"insider"},{"id":5113403,"accession":"0001209191-21-060752","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-060752","line_url":"/filing/0001209191-21-060752#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":310.0,"shares_display":"310","price_per_share":81.14,"price_display":"81.14","price_state":"stated","total_value":25153.4,"total_display":"25,153.40","total_whole":"25,153","shares_owned_after":28358.0,"shares_owned_after_display":"28,358","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-14","filed_date":"2021-10-18","scope":"insider"},{"id":5430203,"accession":"0001209191-21-055362","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-055362","line_url":"/filing/0001209191-21-055362#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7336.0,"shares_display":"7,336","price_per_share":100.65,"price_display":"100.65","price_state":"stated","total_value":738368.4,"total_display":"738,368.40","total_whole":"738,368","shares_owned_after":28668.0,"shares_owned_after_display":"28,668","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-08","filed_date":"2021-09-09","scope":"insider"},{"id":4377115,"accession":"0001209191-21-040108","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-040108","line_url":"/filing/0001209191-21-040108#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1329.0,"shares_display":"1,329","price_per_share":100.0,"price_display":"100.00","price_state":"stated","total_value":132900.0,"total_display":"132,900.00","total_whole":"132,900","shares_owned_after":28668.0,"shares_owned_after_display":"28,668","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-10","filed_date":"2021-06-11","scope":"insider"},{"id":4728706,"accession":"0001209191-21-031388","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-031388","line_url":"/filing/0001209191-21-031388#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":313.0,"shares_display":"313","price_per_share":113.67,"price_display":"113.67","price_state":"stated","total_value":35578.71,"total_display":"35,578.71","total_whole":"35,579","shares_owned_after":29997.0,"shares_owned_after_display":"29,997","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-06","filed_date":"2021-05-10","scope":"insider"},{"id":4259787,"accession":"0001209191-21-017559","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-017559","line_url":"/filing/0001209191-21-017559#line-3","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3970.0,"shares_display":"3,970","price_per_share":138.17,"price_display":"138.17","price_state":"stated","total_value":548534.9,"total_display":"548,534.90","total_whole":"548,535","shares_owned_after":30227.0,"shares_owned_after_display":"30,227","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-01","filed_date":"2021-03-03","scope":"insider"},{"id":2344994,"accession":"0001209191-20-056428","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-056428","line_url":"/filing/0001209191-20-056428#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9903.0,"shares_display":"9,903","price_per_share":100.12,"price_display":"100.12","price_state":"stated","total_value":991488.36,"total_display":"991,488.36","total_whole":"991,488","shares_owned_after":24061.0,"shares_owned_after_display":"24,061","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-30","filed_date":"2020-11-02","scope":"insider"},{"id":3261123,"accession":"0001209191-20-056344","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-056344","line_url":"/filing/0001209191-20-056344#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":97.0,"shares_display":"97","price_per_share":100.0,"price_display":"100.00","price_state":"stated","total_value":9700.0,"total_display":"9,700.00","total_whole":"9,700","shares_owned_after":23968.0,"shares_owned_after_display":"23,968","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-28","filed_date":"2020-10-30","scope":"insider"},{"id":2444563,"accession":"0001209191-20-055179","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-055179","line_url":"/filing/0001209191-20-055179#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":325.0,"shares_display":"325","price_per_share":88.0,"price_display":"88.00","price_state":"stated","total_value":28600.0,"total_display":"28,600.00","total_whole":"28,600","shares_owned_after":23968.0,"shares_owned_after_display":"23,968","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-14","filed_date":"2020-10-16","scope":"insider"},{"id":2444494,"accession":"0001209191-20-054710","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-054710","line_url":"/filing/0001209191-20-054710#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":95.0,"price_display":"95.00","price_state":"stated","total_value":950000.0,"total_display":"950,000.00","total_whole":"950,000","shares_owned_after":24293.0,"shares_owned_after_display":"24,293","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-08","filed_date":"2020-10-13","scope":"insider"},{"id":2838438,"accession":"0001209191-20-054110","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-054110","line_url":"/filing/0001209191-20-054110#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":90.0,"price_display":"90.00","price_state":"stated","total_value":900000.0,"total_display":"900,000.00","total_whole":"900,000","shares_owned_after":24293.0,"shares_owned_after_display":"24,293","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-06","filed_date":"2020-10-07","scope":"insider"},{"id":3284423,"accession":"0001209191-20-051900","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-051900","line_url":"/filing/0001209191-20-051900#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":85.0,"price_display":"85.00","price_state":"stated","total_value":850000.0,"total_display":"850,000.00","total_whole":"850,000","shares_owned_after":24293.0,"shares_owned_after_display":"24,293","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-23","filed_date":"2020-09-24","scope":"insider"},{"id":2141942,"accession":"0001209191-20-047456","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-047456","line_url":"/filing/0001209191-20-047456","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12370.0,"shares_display":"12,370","price_per_share":88.43042037186743,"price_display":"88.43","price_state":"stated","total_value":1093884.3,"total_display":"1,093,884.30","total_whole":"1,093,884","shares_owned_after":26663.0,"shares_owned_after_display":"26,663","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-17","filed_date":"2020-08-19","scope":"insider","n_lines":2},{"id":2436153,"accession":"0001209191-20-030707","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-030707","line_url":"/filing/0001209191-20-030707#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2722.0,"shares_display":"2,722","price_per_share":74.715,"price_display":"74.72","price_state":"stated","total_value":203374.23,"total_display":"203,374.23","total_whole":"203,374","shares_owned_after":27312.0,"shares_owned_after_display":"27,312","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-18","filed_date":"2020-05-19","scope":"insider"},{"id":8646643,"accession":"0001209191-19-038876","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-038876","line_url":"/filing/0001209191-19-038876#line-3","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1226.0,"shares_display":"1,226","price_per_share":61.5,"price_display":"61.50","price_state":"stated","total_value":75399.0,"total_display":"75,399.00","total_whole":"75,399","shares_owned_after":17650.0,"shares_owned_after_display":"17,650","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-06-24","filed_date":"2019-06-24","scope":"insider"},{"id":8646640,"accession":"0001209191-19-038876","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-038876","line_url":"/filing/0001209191-19-038876#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1489.0,"shares_display":"1,489","price_per_share":63.01,"price_display":"63.01","price_state":"stated","total_value":93821.89,"total_display":"93,821.89","total_whole":"93,822","shares_owned_after":18876.0,"shares_owned_after_display":"18,876","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-06-21","filed_date":"2019-06-24","scope":"insider"},{"id":8316224,"accession":"0001209191-19-026669","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-026669","line_url":"/filing/0001209191-19-026669#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":468.0,"shares_display":"468","price_per_share":68.3,"price_display":"68.30","price_state":"stated","total_value":31964.4,"total_display":"31,964.40","total_whole":"31,964","shares_owned_after":19580.0,"shares_owned_after_display":"19,580","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-29","filed_date":"2019-04-30","scope":"insider"},{"id":9270854,"accession":"0001209191-19-025104","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-025104","line_url":"/filing/0001209191-19-025104#line-1","is_derivative":false,"issuer_cik":"0001677455","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001677455","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":886.0,"shares_display":"886","price_per_share":65.52,"price_display":"65.52","price_state":"stated","total_value":58050.72,"total_display":"58,050.72","total_whole":"58,051","shares_owned_after":20296.0,"shares_owned_after_display":"20,296","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-05","filed_date":"2019-04-17","scope":"insider"},{"id":9270712,"accession":"0001209191-18-054521","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-054521","line_url":"/filing/0001209191-18-054521#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":78.53,"price_display":"78.53","price_state":"stated","total_value":392650.0,"total_display":"392,650.00","total_whole":"392,650","shares_owned_after":14181.0,"shares_owned_after_display":"14,181","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-08-21","filed_date":"2018-10-09","scope":"insider"},{"id":6905382,"accession":"0001209191-18-047845","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-047845","line_url":"/filing/0001209191-18-047845#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":78.53,"price_display":"78.53","price_state":"stated","total_value":392650.0,"total_display":"392,650.00","total_whole":"392,650","shares_owned_after":9181.0,"shares_owned_after_display":"9,181","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-08-21","filed_date":"2018-08-21","scope":"insider"},{"id":6078836,"accession":"0001209191-18-038995","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-038995","line_url":"/filing/0001209191-18-038995#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1226.0,"shares_display":"1,226","price_per_share":82.77,"price_display":"82.77","price_state":"stated","total_value":101476.02,"total_display":"101,476.02","total_whole":"101,476","shares_owned_after":14181.0,"shares_owned_after_display":"14,181","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-21","filed_date":"2018-06-21","scope":"insider"},{"id":6604814,"accession":"0001209191-18-029310","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-029310","line_url":"/filing/0001209191-18-029310#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001677455","owner_name":"Parschauer Karah Herdman","owner_display_name":"Parschauer Karah Herdman","owner_url":"/insider/0001677455","role":"Officer (EVP and General Counsel)","role_mark":"O","role_mark_label":"Officer (EVP and General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1465.0,"shares_display":"1,465","price_per_share":60.0,"price_display":"60.00","price_state":"stated","total_value":87900.0,"total_display":"87,900.00","total_whole":"87,900","shares_owned_after":16056.0,"shares_owned_after_display":"16,056","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-10","filed_date":"2018-05-10","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":39,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":39,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":39},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001515673","name":"Ultragenyx Pharmaceutical Inc.","url":"/issuer/0001515673","role":"Officer (EVP and Chief Legal Officer)","n_filings":33,"first_seen":"2018-05-10","last_seen":"2026-08-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001570562","name":"Evolus, Inc.","url":"/issuer/0001570562","role":"Director","n_filings":2,"first_seen":"2024-02-02","last_seen":"2025-03-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001677455","retrieved_at":"2026-08-22T23:46:18+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}